Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IHL-42X for obstructive sleep apnoea
ACTRN12619001103156Phase 3Not yet recruiting
- Sponsor
- Cannvalate
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing IHL-42X with Placebo (2 arms). Primary endpoint: Apnoea Hypopnea Index. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
IHL-42X
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12619001103156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001103156.